title: Patient satisfaction after the treatment of glabellar lines with Botulinum toxin type A (Speywood Unit): a multi-centre European observational study.
abstract: BACKGROUND
  Whilst the efficacy and safety of glabella complex treatment with botulinum toxin type A (Speywood Unit) [BoNT-A (s.U)] has been comprehensively studied, there are very few trials on patient-reported outcomes and patient satisfaction associated with this treatment.
  
  
  OBJECTIVE
  To assess the level of patient satisfaction 3 weeks and 4 months after the treatment of glabellar lines with BoNT-A (s.U).
  
  
  METHODS
  This is a multi-centre, prospective, non-interventional observational study carried out in France, Germany, Spain and the United Kingdom. Subjects were eligible if the investigator had already decided to prescribe BoNT-A (s.U), according to the labelling. Subjects completed a questionnaire at both 3 weeks and 4 months after treatment.
  
  
  RESULTS
  About 533 subjects completed at least one of the two questionnaires. About half of the subjects (47.9%) were naive to BoNT-A treatment of the glabella, while 50.6% had previously received another product. A high level of satisfaction was observed after the treatment, with 94.7% and 89.6% of subjects being satisfied or very satisfied with the aesthetic outcome at week 3 and month 4, respectively. Treatment was safe and well tolerated, as directly determined in the survey. Major reasons for satisfaction included the positive aesthetic outcome, a natural appearance, a rested look and comfort of injection. Most subjects felt the treatment brought them 'harmony', 'self-esteem/confidence' or 'youth'. Of the subjects who had previously been treated with another product, 51.2% considered the results obtained in the present study with BoNT-A (s.U) were better.
  
  
  CONCLUSIONS
  Treatment of the glabellar lines with BoNT-A (s.U) led to a high level of patient satisfaction and a more positive self-perception up to 4 months after the treatment, regardless of whether the patients were naive or not to BoNT-A treatment.
authors.affiliation: Medikas, Somerset, UK.
authors.forename: B
authors.initials: B
authors.lastname: Molina
authors.affiliation: Clinique de l'ocean, Quimper, France.
authors.forename: Y
authors.initials: Y
authors.lastname: Grangier
authors.affiliation: Private Practice, Paris, France.
authors.forename: B
authors.initials: B
authors.lastname: Mole
authors.affiliation: Institut Dra Natalia Ribe, Barcelona, Spain.
authors.forename: N
authors.initials: N
authors.lastname: Ribe
authors.affiliation: Private Practice, Sevilla, Spain.
authors.forename: L
authors.initials: L
authors.lastname: Martín Diaz
authors.affiliation: Dermatologikum, Hamburg, Germany.
authors.forename: W
authors.initials: W
authors.lastname: Prager
authors.affiliation: Galderma R&D, Sophia Antipolis, France.
authors.forename: F
authors.initials: F
authors.lastname: Paliargues
authors.affiliation: Galderma R&D, Sophia Antipolis, France.
authors.forename: N
authors.initials: N
authors.lastname: Kerrouche
mesh_terms: D000293:Adolescent; D000328:Adult; D019274:Botulinum Toxins, Type A / Q000009:adverse effects*; D005060:Europe; D005260:Female; D005500:Follow-Up Studies; D005546:Forehead; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D009465:Neuromuscular Agents / Q000008:administration & dosage; D017060:Patient Satisfaction; D011446:Prospective Studies; D015595:Skin Aging / Q000187:drug effects*; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A